Shionogi gets choosy as it sets global R&D priorities
This article was originally published in Scrip
Executive Summary
Shionogi may be dogged by lingering perceptions that it is a Japan-focused firm heavily reliant on domestic sales of aging anti-infectives with a relatively weak R&D portfolio.